drugset / Trial / NCT05048901
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Phase 1/2
Recruiting
49 enrolled
National Health Research Institutes, Taiwan
Changhua Christian Hospital · collabChina Medical University Hospital · collabKaohsiung Medical University Chung-Ho Memorial Hospital · collabMackay Memorial Hospital · collabNational Cheng-Kung University Hospital · collabNational Taiwan University Hospital · collabTaichung Veterans General Hospital · collabTaipei Veterans General Hospital, Taiwan · collabTri-Service General Hospital (TSGH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of small molecule kinase inhibitor or well-differentiated (W-D) G3 GEP-NET who failed to one line of small molecule kinase inhibitor or chemotherapy.
Timeline
- Start
- 2021-09-17
- Primary completion
- 2027-08-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |
| Subject | Lanreotide | Other / unclassified | 120 mg | Subcutaneous |